Heparan sulfate proteoglycans and triglyceride-rich lipoprotein metabolism

Current Opinion in Lipidology

Volumn 19, Issue 3, 2008, Pages 307-313

  Bishop, Joseph R ^a   Stanford, Kristin I ^a,b   Esko, Jeffrey D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cholesterol; Lipoprotein clearance; Proteoglycans; Sulfation; Triglycerides

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEOHEPARAN SULFATE; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE;

BINDING SITE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; LIPID TRANSPORT; LIPOPROTEIN METABOLISM; LIVER; LIVER CELL; MUTATION; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW; SULFATION; TRANSPORT KINETICS;

ANIMALS; BINDING SITES; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; LIPASE; LIPOPROTEINS; TRIGLYCERIDES;

MUS;

EID: 43249093217     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3282feec2d     Document Type: Review

References (70)

1. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298:299-308.
2. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298:309-316.
3. Havel RJ, Hamilton RL. Hepatic catabolism of remnant lipoproteins: where the action is. Arterioscler Thromb Vasc Biol 2004; 24:213-215.
4. Weiss P, Ashwell G. The asialoglycoprotein receptor: properties and modulation by ligand. Prog Clin Biol Res 1989; 300:169-184.
5. Woodworth A, Baenziger JU. The man/GalNAc-4-SO4-receptor has multiple specificities and functions. Results Probl Cell Differ 2001; 33:123-138.
6. Weigel PH, Yik JHN. Glycans as endocytosis signals: the cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate receptors. Biochim Biophys Acta Gen Subj 2002; 1572:341-363.
7. Brown MS, Kovanen PT, Goldstein JL. Regulation of plasma cholesterol by lipoprotein receptors. Science 1981; 212:628-635.
8. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232:34-47.
9. Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 2001; 108:779-784.
10. Tacken PJ, Hofker MH, Havekes LM, van Dijk KW. Living up to a name: the role of the VLDL receptor in lipid metabolism. Curr Opin Lipidol 2001; 12:275-279.
11. Rohlmann A, Gotthardt M, Hammer RE, Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest 1998; 101:689-695.
12. Fujino T, Asaba H, Kang MJ, et al. Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci U S A 2003; 100:229-234.
13. Williams KJ, Fuki IV. Cell-surface heparan sulfate proteoglycans: dynamic molecules mediating ligand catabolism. Curr Opin Lipidol 1997; 8:253-262.
14. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 1999; 40:1-16.
15. Ji ZS, Sanan DA, Mahley RW. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J Lipid Res 1995; 36:583-592.
16. MacArthur JM, Bishop JR, Wang L, et al. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest 2007; 117:153-164. This paper provides the first genetic evidence showing that heparan sulfate proteoglycans facilitate clearance of hepatic and dietary triglycerides in the liver and that in the absence of LDL receptors they can aid in clearance of cholesterol-rich particles. Moreover, the authors showed that altering endothelial and leukocyte heparan sulfate has no effect on plasma triglycerides.
17. Mahley RW, Huang Y. Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing. J Clin Invest 2007; 117:94-98.
18. Cortes V, Rigotti A. Liver heparan sulfate proteoglycans: old molecules provide new insights on lipoprotein metabolism. Hepatology 2007; 45:1078-1080.
19. Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest 2001; 108:169-173.
20. Oldberg Å, Kjellén L, Höö k M. Cell-surface heparan sulfate. Isolation and characterization of a proteoglycan from rat liver membranes. J Biol Chem 1979; 254:8505-8510.
21. Lyon M, Deakin JA, Gallagher JT. Liver heparan sulfate structure. A novel molecular design. J Biol Chem 1994; 269:11208-11215.
22. Zhang L, Esko JD. Amino acid determinants that drive heparan sulfate assembly in a proteoglycan. J Biol Chem 1994; 269:19295-19299.
23. Zhang L, David G, Esko JD. Repetitive Ser-Gly sequences enhance heparan sulfate assembly in proteoglycans. J Biol Chem 1995; 270:27127-27135.
24. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007; 446:1030-1037. In this review, the authors describe the various functions of heparan sulfate proteoglycans in animal cells, which includes co-receptor activation of growth factors, endocytosis, cell adhesion and motility, and barrier functions in basement membranes.
25. Iozzo RV. Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol 2005; 6:646-656.
26. Haltiwanger RS, Lowe JB. Role of glycosylation in development. Annu Rev Biochem 2004; 73:491-537.
27. Hacker U, Nybakken K, Perrimon N. Heparan sulphate proteoglycans: the sweet side of development. Nat Rev Mol Cell Biol 2005; 6:530-541.
28. Bulow HE, Hobert O. The molecular diversity of glycosaminoglycans shapes animal development. Annu Rev Cell Dev Biol 2006; 22:375-407.
29. Esko JD, Selleck SB. Order out of chaos: Assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 2002; 71:435-471.
30. Coppi A, Tewari R, Bishop JR, et al. Heparan sulfate proteoglycans provide a signal to Plasmodium sporozoites to stop migrating and productively invade host cells. Cell Host Microbe 2007; 2:316-327.
31. Libeu CP, Lund-Katz S, Phillips MC, et al. New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E. J Biol Chem 2001; 276:39138-39144.
32. Vongchan P, Warda M, Toyoda H, et al. Structural characterization of human liver heparan sulfate. Biochim Biophys Acta 2005; 1721:1-8.
33. Dong J, Peters-Libeu CA, Weisgraber KH, et al. Interaction of the N-terminal domain of apolipoprotein E4with heparin. Biochemistry 2001; 40:2826-2834.
34. Saito H, Dhanasekaran P, Nguyen D, et al. Characterization of the heparin binding sites in human apolipoprotein E. J Biol Chem 2003; 278:14782-14787.
35. Horie Y, Fazio S, Westerlund JR, et al. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. J Biol Chem 1992; 267:1962-1968.
36. Ji ZS, Fazio S, Mahley RW. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem 1994; 269:13421-13428.
37. Mann WA, Meyer N, Weber W, et al. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia. J Lipid Res 1995; 36:517-525.
38. Minnich A, Weisgraber KH, Newhouse Y, et al. Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E30 (Arg136->His): association with mild dyslipidemia and double prebeta very low density lipoproteins. J Lipid Res 1995; 36:57-66.
39. Marz W, Hoffmann MM, Scharnagl H, et al. Apolipoprotein E2 (Arg136-> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia. J Lipid Res 1998; 39:658-669.
40. Goldberg IJ, Wagner WD, Pang L, et al. The NH2-terminal region of apolipoprotein B is sufficient for lipoprotein association with glycosaminoglycans. J Biol Chem 1998; 273:35355-35361.
41. Borén J, Olin K, Lee I, et al. Identification of the principal proteoglycan-binding site in LDL: a single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest 1998; 101:2658-2664.
42. Flood C, Gustafsson M, Richardson PE, et al. Identification of the proteoglycan binding site in apolipoprotein B48. J Biol Chem 2002; 277:32228-32233.
43. Wong K, Ryan RO. Characterization of apolipoprotein A-V structure and mode of plasma triacylglycerol regulation. Curr Opin Lipidol 2007; 18:319-324. This review describes our current understanding of apoA-V structure and its role in triglyceride metabolism in the periphery. ApoA-V binds to heparan sulfate, which may faciliate the interaction of Lpl with its substrate lipoproteins.
44. Goldberg IJ, Merkel M. Lipoprotein lipase: physiology, biochemistry, and molecular biology. Front Biosci 2001; 6:D388-405.
45. Parthasarathy N, Goldberg IJ, Sivaram P, et al. Oligosaccharide sequences of endothelial cell surface heparan sulfate proteoglycan with affinity for lipoprotein lipase. J Biol Chem 1994; 269:22391-22396.
46. Spillmann D, Lookene A, Olivecrona G. Isolation and characterization of low sulfated heparan sulfate sequences with affinity for lipoprotein lipase. J Biol Chem 2006; 281:23405-23413.
47. Anfinsen CB, Boyle E, Brown RK. The role of heparin in lipoprotein metabolism. Science 1952; 115:583-586.
48. Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 2007; 5:279-291. These authors provide genetic evidence that glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) plays a crucial role in the lipolytic processing of chylomicron by binding LPL and chylomicron substrates. The work challenges the dogma that LPL is bound predominantly to heparan sulfate proteoglycans.
49. Young SG, Davies BS, Fong LG, et al. GPIHBP1: an endothelial cell molecule important for the lipolytic processing of chylomicrons. Curr Opin Lipidol 2007; 18:389-396.
50. Wallinder L, Peterson J, Olivecrona T, Bengtsson-Olivecrona G. Hepatic and extrahepatic uptake of intravenously injected lipoprotein lipase. Biochim Biophys Acta 1984; 795:513-524.
51. Olivecrona T, Bengtsson-Olivecrona G. Lipoprotein lipase and hepatic lipase. Curr Opin Lipidol 1993; 4:187-196.
52. Williams KJ, Fless GM, Petrie KA, et al. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. Roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J Biol Chem 1992; 267:13284-13292.
53. Aikawa J, Grobe K, Tsujimoto M, Esko JD. Multiple isozymes of heparan sulfate/heparin GlcNAc N-deacetylase/N-sulfotransferase: structure and activity of the fourth member, NDST4. J Biol Chem 2001; 276:5876-5882.
54. Postic C, Magnuson MA. DNA excision in liver by an albumin-Cre transgene occurs progressively with age. Genesis 2000; 26:149-150.
55. Condac E, Silasi-Mansat R, Kosanke S, et al. Polycystic disease caused by deficiency in xylosyltransferase 2, an initiating enzyme of glycosaminoglycan biosynthesis. Proc Natl Acad Sci U S A 2007; 104:9416-9421.
56. Fuki IV, Kuhn KM, Lomazov IR, et al. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J Clin Invest 1997; 100:1611-1622.
57. Zeng BJ, Mortimer BC, Martins IJ, et al. Chylomicron remnant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes. J Lipid Res 1998; 39:845-860.
58. Wilsie LC, Gonzales AM, Orlando RA. Syndecan-1 mediates internalization of apoE-VLDL through a low density lipoprotein receptor-related protein (LRP)-independent, nonclathrin-mediated pathway. Lipids Health Dis 2006; 5:23.
59. Cortes V, Amigo L, Donoso K, et al. Adenovirus-mediated hepatic syndecan-1 overexpression induces hepatocyte proliferation and hyperlipidaemia in mice. Liver Int 2007; 27:569-581.
60. Tkachenko E, Rhodes JM, Simons M. Syndecans: new kids on the signaling block. Circ Res 2005; 96:488-500.
61. Yanagishita M, Hascall V. Cell surface heparan sulfate proteoglycans. J Biol Chem 1992; 267:9451-9454.
62. Takeuchi Y, Yanagishita M, Hascall VC. Recycling of transferrin receptors and heparan sulfate proteoglycans in a rat parathyroid cell line. J Biol Chem 1992; 267:14685-14690.
63. Fransson LA, Belting M, Cheng F, et al. Novel aspects of glypican glycobiology. Cell Mol Life Sci 2004; 61:1016-1024.
64. Zimmermann P, Zhang Z, Degeest G, et al. Syndecan recycling [corrected] is controlled by syntenin-PIP2 interaction and Arf6. Dev Cell 2005; 9:377-388.
65. Truong TQ, Auger A, Denizeau F, Brissette L. Analysis of low-density lipoprotein catabolism by primary cultures of hepatic cells from normal and low-density lipoprotein receptor knockout mice. Biochim Biophys Acta 2000; 1484:307-315.
66. Auger A, Truong TQ, Rhainds D, et al. Low and high density lipoprotein metabolism in primary cultures of hepatic cells from normal and apolipoprotein E knockout mice. Eur J Biochem 2001; 268:2322-2330.
67. Payne CK, Jones SA, Chen C, Zhuang X. Internalization and trafficking of cell surface proteoglycans and proteoglycan-binding ligands. Traffic 2007; 8:389-401. This paper describes the channeling of polycationic ligands bound to cell surface proteoglycans via clathrin-independent and caveolin-independent endocytic pathways, which would distinguish uptake of lipoproteins via proteoglycans from the LDL receptor.
68. Shimano H, Namba Y, Ohsuga J, et al. Secretion-recapture process of apolipoprotein E in hepatic uptake of chylomicron remnants in transgenic mice. J Clin Invest 1994; 93:2215-2223.
69. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007; 176:1113-1120.
70. Rodriguez-Lee M, Bondjers G, Camejo G. Fatty acid-induced atherogenic changes in extracellular matrix proteoglycans. Curr Opin Lipidol 2007; 18:546-553. The authors summarize data showing that nonesterified fatty acids change the expression and properties of the extracellular matrix proteoglycans of arterial and hepatic cells, which affects the affinity for VLDL.